Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy

Francesco Pasqualetti1 · Paola Orlandi2 · Vittorio Simeon3 · Martina Cantarella1 · Daniela Giuliani4 · Teresa Di Desidero2 · Alessandra Gonnelli1 · Durim Delishaj1 · Giuseppe Lombardi5 · Andrea Sechi6 · Marc Sanson6 · Vittorina Zagonel5 · Fabiola Paiar1 · Romano Danesi2 · Salvatore Guarini4 · Guido Bocci2

Received: 1 December 2016 / Accepted: 18 January 2017 / Published online: 1 February 2017
© Springer Science+Business Media New York 2017

Abstract Melanocortins are peptides with well-recognized antiinflammatory and neuroprotective activity. No data are currently available on melanocortin receptor-4 (MC4R) gene polymorphisms and tumors, including glioblastomas (GBMs), or their relationship with radiotherapy or chemotherapy. The aim of this study was to evaluate the possible predictive/prognostic role of the MC4R SNPs on GBM patients. Fifty-five patients with a proven diagnosis of GBM, treated with radiotherapy and temozolomide, were consecutively enrolled. MC4R gene SNPs (rs17782313, rs489693, rs8087522, rs17700633) were analyzed by a validated TaqMan® SNP genotyping assays. Univariate and multivariate analyses were performed. A P < 0.0125 (Bonferroni's correction) was considered significant (Clinicaltrial.gov identifier NCT02458508). The median progression-free survival (PFS) and median overall survival (OS) of these patients were 9.54 (95% CI 5.4–14.3) months and 24.9 (95% CI 17.8–34.6) months, respectively. The MC4R rs489693 AA genotype was significantly associated with a shorter PFS and OS. Indeed, with regard to PFS, patients harboring the rs489693 AA genotype had a median PFS of 2.99 months whereas patients with AC/CC genotypes had a median PFS of 10.82 months (P = 0.009). Interestingly, the rs489693 AA patients also had a lower median OS as compared with the median OS of the AC/CC genotypes (10.75 vs. 29.5 months, respectively, P = 0.0001). This study suggests that the MC4R rs489693 AA genotype is significantly associated with a shorter PFS and OS in patients treated with radiotherapy and temozolomide. These findings represent a relevant effort to identify novel clinical markers for RT–CT therapy in GBM to be validated in future pharmacogenetic clinical trials.

Keywords Glioblastoma · Melanocortin receptor-4 · Polymorphism · Radiotherapy · Temozolomide

Introduction Glioblastoma (GBM) represents the most frequent malignant primary brain tumor and, despite the latest advances recorded...
over the past decade, remains a lethal disease with a dismal prognosis [1]. The treatment of glioblastomas remains difficult in that no contemporary treatments are curative. The current standard of care for newly diagnosed GBM was established in 2005, after the conclusion of the study led by Stupp [2] and nowadays, upfront concomitant radiotherapy–chemotherapy (RT–CT) with temozolomide (TMZ) represents the gold standard of care. Unfortunately, the recurrence rate after concomitant RT-CT and the overall survival (OS) are still unsatisfactory; indeed, 90% of patients experienced a disease relapse and the median OS in clinical trial population was 15–18 months [3]. Despite important advances in the characterization of genomic and microenvironment alterations in glioblastoma, targeted agents have shown minimal efficacy in clinical trials to date, and patient survival remains poor. Indeed, large placebo-controlled randomized phase III trials aimed at targeting the angiogenic phenotype of glioblastoma using bevacizumab (an antiangiogenic endothelial growth factor, VEGF) or cilengitide (an integrin inhibitor) failed to show an improvement in overall survival compared with the current standard of care [4].

Melanocortins are peptides with well-recognized antiinflammatory and neuroprotective activity [5, 6]. Of the five known melanocortin receptors, only subtype 4 is present in astrocytes [7]. Melanocortin receptor-4 (MC4R) [8] has been shown to mediate melanocortin effects on energy homeostasis [9], inflammation [10], neuroprotection, and neurogenesis [6, 8, 11, 12] and, recently, to modulate astrocyte functions [7]. Recently, in experimental brain ischemia, treatment with melanocortins acting at MC4Rs induced neural stem/progenitor cell proliferation by triggering the canonical wingless-type MMTV integration site (Wnt)-3A/β-catenin and Sonic hedgehog (Shh) signaling pathway [13]. Moreover, Caruso and colleagues demonstrated that MC4R activation by α-melanocyte-stimulating hormone (α-MSH) protects astrocytes from apoptosis by decreasing caspase-3 activity and stimulates proliferative effects in 7-day-old cultured astrocytes [7].

MC4R gene polymorphisms have emerged as new and promising biomarkers for the prediction of weight gain in patients treated with antipsychotic drugs [14]. Several independent genome-wide association studies identified the polymorphism MC4R rs17782313 to be linked to increased body weight and obesity [15], having shown an effect on body mass index (BMI) in different populations [16, 17]. Moreover, a direct role in the interaction between fat mass- and obesity-associated (FTO) and MC4R gene polymorphisms in breast cancer development has been recently demonstrated [18]. On the other hand, the MC4R rs17782313 polymorphism was not related to endometrial cancer risk [19] although overweight and obesity are strongly associated with this type of cancer. Recently, no evidences were found supporting that individual variants in MC4R gene are associated with risk of colorectal cancer [20]. No data are currently available on MC4R gene polymorphisms and GBMs or their relationship with the success or failure to radio- or chemotherapy. The aim of this study was to evaluate the possible prognostic/predictive role of the MC4R SNPs on GBM therapy.

Patients and Methods

This was an exploratory, multicenter retrospective pharmacogenetic study. Fifty-five patients with age ≥18 years and diagnosis of GBM were recruited, consecutively, and they were assessed for the present pharmacogenetic study. The patients evaluated in this study were treated with post-operative concomitant RT and CT. RT was delivered to surgical bed plus residual disease with 2 cm of margin; the total dose delivered was 60 Gy in 30 fractions. CT was represented by TMZ that was administered at the dose of 75 mg/m²/day during the RT time and of 150–200 mg/m²/day for 5 days every 28 days during 6–12 cycles, until disease progression or toxicity occurrence. Disease relapse was assessed 1 month after the end of concomitant RT–CT with a contrast magnetic resonance imaging (MRI) and every 3 months for the first 3 years, then every 4 months (if a pseudoprogression was suspected, a new MRI was performed after 6 weeks). Macdonald criteria were used to define disease control [21]. Each patient entering the study signed the informed consent. The protocol was approved by the Comitato Etico di Area Vasta Nord Ovest (CEAVNO), Pisa, Italy (CEAVNO prot. n. 17013; clinicaltrial.gov identifier NCT02458508) and by the ethic committees of all participating centers.

SNP Selection

The MC4R gene SNPs (rs17782313, rs489693, rs8087522, rs17700633) included in our study (supplementary Table 1) were selected on the basis of four main considerations: (i) these SNPs have been described to be associated with human diseases such as obesity and diabetes or with antipsychotic-induced weight gain but not with cancer; (ii) only the rs17782313 has been significantly associated with risk of breast cancer [18] but not in the endometrial [19] and colorectal cancer [20]; (iii) thus far, no genetic analysis has been reported on the chosen MC4R SNPs and GBM; and (iv) although for the chosen SNPs the phenotypic effects are still undefined (i.e., the modulation of the gene expression or activity of the receptor), we decided to include them in our pilot research because of the possibility that some genotypes or haplotypes could determine a statistical effect on patient’s survival.

Genotyping Analyses

Blood samples (3 ml) were collected in ethylenediaminetetraacetic acid (EDTA) tubes and stored at −80 °C. Germline DNA extraction was performed using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA). Allelic discrimination of genes was performed using an ABI PRISM 7900 SDS
(Applied Biosystems, Carlsbad, CA, USA) and with validated TaqMan® SNP genotyping assays (i.e., C_32667060_10, rs17782313; C_3058718_10, rs489693; C_29004626_10, rs8087522; C_32666984_10, rs17700633; Applied Biosystems). Polymerase chain reaction (PCR) reactions were carried out according to the manufacturer’s protocol. Genotyping was not performed until an adequate number of events (>80% on study population) was reported in terms of progression-free survival (PFS).

Statistical Analysis

The statistical analysis was performed by V. Simeon. All polymorphisms were analyzed for deviation from the Hardy–Weinberg Equilibrium (HWE) through comparison between observed allelic distributions with those expected from the HWE by on χ² test. Linkage disequilibrium (LD) between markers in MC4R (n = 4) was analyzed using Haploview software package [22]. The difference in PFS or OS between genotype profiles was assessed with the log-rank test and the Kaplan–Meier method to evaluate survival curves. A Cox proportional hazards model, with the genotype profiles of each individual polymorphism and the clinical and pathological patient characteristics individually correlated with the PFS or OS, was used to calculate the adjusted hazards ratio (HR) and the 95% confidence interval (95% CI). In these analyses, we used Bonferroni’s correction and the P value <0.0125 (0.05/4 SNPs = 0.0125) was accepted as statistically significant. The Kaplan–Meier and Cox proportional hazard analyses were performed using the STATA package version 11.0 (StataCorp). Where an association was found to be significant on univariate analyses, multivariate analysis was performed. PFS was defined as the period of time from the beginning of the RT–CT treatment to the first observation of disease progression as above described, or death from any cause. OS was calculated from the date of the diagnosis to the date of death/lost to follow-up. Due to the small sample size in OS data, multivariate analysis was restricted to only three variables. Decision on best model was performed calculating Bayesian Information Criterion (BIC) [23].

PHASE software v2.1 [24] was used to perform haplotype analysis for MC4R regions separately. Only common haplotypes with a frequency ≥5% were included in Cox survival analysis. The most common haplotype was used as the reference and were provided hazard ratios (HR) for a given haplotype relative to reference haplotype.

Results

Fifty-five patients with diagnosis of GBM were enrolled into the study and genotyped for MC4R SNPs. Details about genotypes and allele frequencies of all SNPs in the entire population are reported in supplementary Table 1; all the SNPs were in HWE. The clinical characteristics of the 55 patients are summarized in Table 1. All patients were clinically assessable for PFS and OS. The PFS of these patients was 9.54 months (95% CI 5.4–14.3), whereas the OS resulted 24.9 months (95% CI 17.8–34.6). The hematological toxicity (i.e., leucopenia and thrombocytopenia) was recorded during the RT–CT treatment and reported in supplementary Table 2.

The univariate Cox regression analysis showed the role of the age at diagnosis (HR = 1.03; P = 0.035) and of the frontal localization (HR = 0.46; P = 0.028) of the disease in determining the PFS of this group of patients (supplementary Table 3). The same univariate analysis confirmed the role of the frontal lobe site (HR = 0.38; P = 0.026) of the disease in determining the OS with the addition of performance status (HR = 0.98; P = 0.03) and the administered lines of chemotherapy (HR = 0.6; P = 0.031) (supplementary Table 4).

Table 1  Characteristics of patients

| Characteristics | Sex, n (%) | Weight, Mean ± SD | Age at diagnosis, Mean ± SD | Body mass index (BMI), Mean ± SD | Previous radiotherapy, n (%) | Lines of chemotherapy, n (%) | Frontal lobe site, n (%) | Performance status, Mean ± SD |
|-----------------|------------|-------------------|-----------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|-----------------------------|
|                 | Male       | 73.3 ± 12.9       | 56.6 ± 12.4                 | 25.1 ± 3.97                   | No                          | 25 (45.45)                  | No                       | 78.9 ± 19.7                 |
|                 | Female     | 72.5 (52–103)     | 58 (24–80)                  | 25 (21.6–27.8)                | Yes                         | 18 (30.91)                  | Yes                      | 78.9 ± 19.7                 |
|                 |            |                   |                             |                               | Unknown                      | 3 (5.45)                    | Unknown                  |                             |
|                 |            |                   |                             |                               |                             | 25 (45.45)                  |                         |                             |
|                 |            |                   |                             |                               |                             | 16 (29.09)                  |                         |                             |
|                 |            |                   |                             |                               |                             | 3 (5.45)                    |                         |                             |
|                 |            |                   |                             |                               |                             | 1 (1.82)                    |                         |                             |
|                 |            |                   |                             |                               |                             | 34 (61.82)                  |                         |                             |
|                 |            |                   |                             |                               |                             | 17 (30.91)                  |                         |                             |
|                 |            |                   |                             |                               |                             | 4 (7.27)                    |                         |                             |

Table 1 Characteristics of patients
A statistically significant association with PFS in univariate Cox regression analysis, either under an additive, dominant, or recessive model (as illustrated in Table 2), was found with MC4R rs489693 that reaches the significance threshold in both the additive ($P = 0.012$) and dominant models ($P = 0.009$). Indeed, the PFS values of MC4R rs489693 AA, CA, and CC patients were 2.99 (95% CI 2.3–4.5), 9.77 (95% CI 5.1–22.7), and 10.82 (95% CI 5.4–17.8) months, respectively (Fig. 1a), whereas the PFS of CC/CA genotypes was 10.82 (95% CI 5.7–15.8) months vs. 2.99 (95% CI 2.3–4.5) months of the harboring AA patients (Fig. 1b). Interestingly, the same SNP maintained the same statistically significant association with OS ($n = 53$) in univariate Cox regression analysis, either under an additive ($P = 0.0001$) or a dominant ($P = 0.0001$) model as shown in Table 3. Indeed, the OS values of MC4R rs489693 AA, CA, and CC patients were 10.75 (95% CI 7.4–12.5), 25.75 (95% CI 13.5–57.3), and 34.1 (95% CI 17.7–73.2) months, respectively (Fig. 1c), whereas the OS of CC/CA genotypes was 29.5 (95% CI 22.6–40.1) months vs. 10.75 (95% CI 7.4–12.5) months of the harboring AA patients (Fig. 1d).

Furthermore, the haplotype analysis of the MC4R genetic region (supplementary Fig. 1a) did not reveal any significant association in univariate Cox regression model and Kaplan–Meier PFS ($n = 55$; supplementary Fig. 2b) and OS ($n = 53$; supplementary Fig. 1c) curves.

Notably, the multivariate analyses adjusted for the age at the diagnosis, frontal lobe localization, and lines of chemotherapy revealed that the MC4R rs489693 AA genotype was the most powerful single factor associated with the PFS (HR = 3.45 and $P = 0.018$ for the additive model; HR = 3.14 and $P = 0.021$ for the dominant model), as described in Table 4. The best models in multivariate analyses with OS data, selected with BIC value (supplementary Table 5), were both additive and dominant models of MC4R rs489693 (HR = 6.1 and $P = 0.004$ for the additive model; HR = 4.9 and $P = 0.006$ for the dominant model) adjusted for performance status and frontal lobe localization (Table 5). The one with the dominant model shows the lowest BIC value with positive to strong evidence to be preferred against the others.

No association between MC4R SNPs and weight of patients at the diagnosis was found (data not shown), as well as between MC4R SNPs and localization of the disease or hematological toxicities (data not shown). Although analyzed in a small subset of patients ($n = 27$) with available tumor tissues, as expected, the tumor O6-methylguanine-DNA methyltransferase (MGMT) methylation significantly increase the PFS (15.8 vs. 5.13 months, $P = 0.02$; $n = 27$; supplementary Fig. 2a) and, even though it did not reach a statistical significance, also the OS (25.9 vs. 17.8 months, $P = 0.25$; $n = 27$; supplementary Fig. 2b).

### Discussion

The present study describes, for the first time, the association between MC4R polymorphisms and survival of GBM patients under RT–CT regimen that consists of TMZ and concomitant RT (60 Gy). In this regard, the individual genetic traits of patients may have a role in the response to chemotherapy or to radio-therapeutic strategies in GBM. Indeed, the TMZ-treated GBM patients harboring the T allele of the MGMT promoter SNP rs16906252 have shown a better survival, independently of the tumor methylation status [25]. However, with the exception of the establish role of MGMT methylation [26], there are currently no validated genetic biomarkers to predict or to monitor favorable clinical response or resistance to concomitant radio- and TMZ therapies [27]. Therefore,

---

**Table 2** Association between each MC4R polymorphism and PFS (univariate Cox regression model)

| ID       | Genotype | Additive model | Dominant model | Recessive model |
|----------|----------|----------------|----------------|----------------|
|          | N        | HR  | P    | 95% CI | N  | HR  | P    | 95% CI | N  | HR  | P    | 95% CI |
| rs17782313 | TT 30 1 | –   | –    | –     | TT/TC 53 1 | –   | –    | –     |
|          | TC 23 1.33 | 0.35 | 0.73–2.42 | TT/TC 53 1 | –   | –    | –     |
|          | CC 2 3.31 | 0.11 | 0.76–14.4 | CC 2 2.92 | 0.14 | 0.69–12.4 |
| rs489693  | CC 30 1 | –   | –    | –     | CC/CA 49 1 | –   | –    | –     |
|          | CA 19 0.97 | 0.93 | 0.51–1.85 | CC/CA 49 1 | –   | –    | –     |
|          | AA 6 3.26 | 0.012 | 1.29–8.22 | AA 6 3.29 | 0.009 | 1.34–8.04 |
| rs8087522 | GG 32 1  | –   | –    | –     | GG/GA 52 1 | –   | –    | –     |
|          | GA 20 0.8 0.5 | 0.43–1.5 | GG/GA 52 1 | –   | –    | –     |
|          | AA 3 0.66 | 0.57 | 0.16–2.8 | AA 3 0.72 | 0.66 | 0.18–3 |
| rs17700633 | GG 35 1 | –   | –    | –     | GG/GA 54 1 | –   | –    | –     |
|          | GA 19 1.82 | 0.055 | 0.98–3.38 | GG/GA 54 1 | –   | –    | –     |
|          | AA 1$^a$ | 1   | –    | –     | AA 1$^a$ | 1   | 1    | 1$^a$ |

A $P$ value $<0.0125$ was defined as statistically significant (Bonferroni’s correction)

$^a$ The value was not determined because of the occurrence of only one AA case
Fig. 1 Kaplan–Meier curves for progression-free survival (PFS) of patients harboring a) \( MC4R \) rs489693 CC, CA, and AA genotypes and b) \( MC4R \) rs489693 CC/CA and AA genotypes. Kaplan–Meier curves for overall survival (OS) of patients harboring c) \( MC4R \) rs489693 CC, CA, and AA genotypes and d) \( MC4R \) rs489693 CC/CA and AA genotypes. 95% CI 95% confidence interval

Table 3  Association between each \( MC4R \) polymorphism and OS (univariate Cox regression model)

| ID       | Additive model | Dominant model | Recessive model |
|----------|----------------|----------------|-----------------|
|          | Genotype | \( N \) | HR | \( P \) | 95% CI | Genotype | \( N \) | HR | \( P \) | 95% CI | Genotype | \( N \) | HR | \( P \) | 95% CI |
| rs17782313 TT | 29 | 1 | – | – | TT/TC | 51 | 1 | – | – |
|            TC | 22 | 1.94 | 0.075 | 0.94–3.9 | TC/CC | 24 | 2.08 | 0.041 | 1.03–4.2 |
|            CC | 2 | 6.1 | 0.022 | 1.3–28.7 | CC | 2 | 4.47 | 0.049 | 1.01–19.9 |
| rs489693    CC | 29 | 1 | – | – | CC/CA | 47 | 1 | – | – |
|            CA | 18 | 1.08 | 0.855 | 0.5–2.4 | CA/AA | 24 | 1.5 | 0.24 | 0.75–3.04 |
|            AA | 6 | 7.02 | 0.0001 | 2.44–20.2 | AA | 6 | 6.8 | 0.0001 | 2.5–18.6 |
| rs8087522   GG | 30 | 1 | – | – | GG/GA | 50 | 1 | – | – |
|            GA | 20 | 0.79 | 0.53 | 0.4–1.65 | GA/AA | 23 | 0.84 | 0.61 | 0.42–1.7 |
|            AA | 3 | 1.23 | 0.78 | 0.3–5.3 | AA | 3 | 1.35 | 0.69 | 0.32–5.7 |
| rs17700633  GG | 34 | 1 | – | – | GG/GA | 52 | 1 | – | – |
|            GA | 18 | 1.44 | 0.36 | 0.66–3.15 | GA/AA | 19 | 1.25 | 0.58 | 0.6–2.7 |
|            AA | 1 | 1 | – | – | AA | 1 | 1 | – | – |

A \( P \) value \(<0.0125\) was defined as statistically significant (Bonferroni’s correction)

\(^a\) The value was not determined because of the occurrence of only one AA case
The impact of commonly reported MC4R variants, usually described in the gain of weight during antipsychotic therapy [30–33], in relation to clinical survival following RT–CT concomitant treatment. In particular, we decided to test the hypothesis that, given the association between MC4R with prevention of astrocyte apoptosis [7], induction of neural stem/progenitor cell proliferation in brain hypoxia [11], neuroprotection, and antiinflammatory activity [6], the MC4R SNPs could have a possible direct role in the modulation of the cytotoxic, and thus therapeutic, effects of radiotherapy and TMZ on GBM or they could influence the prognosis of the disease through their effect on patient’s tumors.

Our results clearly show that there was a robust statistical association between the MC4R rs489693 AA genotype and a shorter progression-free survival of patients treated with the combination of RT and TMZ. Moreover, this association was maintained also in the overall survival, indicating a statistical disadvantage for patients harboring this particular genotype if treated with this standard therapeutic approach for GBM. To our knowledge, no other data are currently available linking polymorphisms of MC4R gene and therapeutic efficacy or toxicity of any type of cancer, including GBM, thus representing a novel, although preliminary, discovery in the field that should be confirmed by wider and prospective pharmacogenetic trials.

One of the hallmarks of GBM is represented by the presence of necrotic areas within the tumor mass, and thus, these areas are commonly characterized by severe hypoxia. Indeed, the hypoxia-inducible factor-1 alpha (HIF-1α) has been reported to play a pivotal role in GBM development and progression because of its characteristic to induce the upregulation of numerous genes such as VEGF [34]. Thus, tumor cells survive acquiring molecular (e.g., VEGF secretion) or genetic changes as the result of the inadequate supply of O2 and nutrients [35, 36]. Indeed, one of the main factors responsible for GBM treatment failure is this hypoxia, while causing apoptotic and necrotic death of normal cells permits to neoplastic cells to develop defense mechanisms [37]. Moreover, several studies have demonstrated that glioma and glioblastoma cells exhibit important resistance to apoptosis after exposure to ionizing radiation [38], as well as the key role of the expression status of B cell lymphoma-2 (Bcl-2) family proteins that are fundamental for the activation of the apoptosis pathway in GBM after TMZ administration, even in cancer stem cells [39, 40]. Besides, the antiapoptotic mechanisms of resistance [41] and also the activation of specific pathways such as Wnt-3A/β catenin, Shh, and Notch have been implicated in tumor radio- and chemoresistance [42, 43].

MC4Rs are expressed predominantly in the brain, both on neurons and astrocytes, but they were also detected in adipose tissue and in human skin melanocytes [44]. Although the brain distribution of the MC4 receptor in mice and rats has been extensively studied [44], the mapping of brain human MC4R is still an open field. Moreover, no data are available on MC4R gene and protein expression in GBM or other cancer cells.

**Table 4** Multivariate Cox regression model of PFS

|                       | HR   | P    | 95% CI         |
|-----------------------|------|------|----------------|
| Age at diagnosis      | 1.01 | 0.311| 0.98–1.04      |
| Lines of chemotherapy | 0.82 | 0.311| 0.55–1.2       |
| Frontal lobe site     | 0.46 | 0.058| 0.2–1.03       |
| rs489693 additive     |      |      |                |
| CC                    | 1    | –    | –              |
| CA                    | 1.25 | 0.558| 0.6–2.6        |
| AA                    | 3.45 | 0.018| 1.23–9.6       |
| Age at diagnosis      | 1.01 | 0.291| 0.98–1.04      |
| Lines of chemotherapy | 0.81 | 0.297| 0.55–1.2       |
| Frontal lobe site     | 0.50 | 0.07 | 0.24–1.06      |
| rs489693 dominant     |      |      |                |
| CC/CA                 | 1    | –    | –              |
| AA                    | 3.14 | 0.021| 1.2–8.3        |

Lines of chemotherapy is represented as an ordinal variable.

**Table 5** Multivariate Cox regression model of OS

|                       | HR   | P    | 95% CI         |
|-----------------------|------|------|----------------|
| Performance status    | 0.99 | 0.39 | 0.97–1.01      |
| Frontal lobe site     | 0.42 | 0.052| 0.17–1.01      |
| rs489693 dominant     |      |      |                |
| CC/CA                 | 1    | –    | –              |
| AA                    | 4.9  | 0.006| 1.6–15.8       |
| Performance status    | 0.99 | 0.37 | 0.97–1.01      |
| Frontal lobe site     | 0.38 | 0.035| 0.15–0.94      |
| rs489693 additive     |      |      |                |
| CC                    | 1    | –    | –              |
| CA                    | 1.64 | 0.28 | 0.7–4.02       |
| AA                    | 6.1  | 0.004| 1.76–21.2      |

HR hazard ratio, CI confidence interval.
although our group has demonstrated the presence of functional MC4Rs in at least two human GBM cell lines (Bocci G., unpublished data). Although at a first glance the MC4R functions have been described in completely different areas such the control of weight, it is not surprising that MC4R may share more than a simple statistical connection with the success of RT-CT therapy and/or prolonged survival in GBM. In fact, it has been demonstrated that MC4R signaling can stimulate both the survival of astrocytes, by decreasing caspase-3 activity and the expression of Bcl-2-associated X protein (Bax) and by increasing the expression of Bcl-2 [45], and the proliferation of neural stem/progenitor cell under hypoxic conditions, by triggering the canonical Wnt-3A/β-catenin and Shh signaling pathway [13]. Moreover, in an animal model of cerebral ischemia and Alzheimer’s disease, the chronic treatment with the melanocortin analog [Nle(4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH), an MC4R agonist, significantly reduced neuron damages, determining the shorter PFS and OS in these GBM cancer patients. Conversely, in patients with a more favorable genetic profile, the MC4R survival signal to cancer cells due to the different genotypes may be reduced and, in the presence of RT and TMZ, tumor cells are less capable to proliferate or survive.

This study recruited, consecutively, 55 patients treated with RT and TMZ at our institution and other centers. An obvious limitation of this work is that the association between the PFS or OS and the MC4R genotype was assessed on a limited number of patients. Thus, initial data from pilot studies should be scrutinized with the most accurate statistical correction [49], as in the present study, where we applied a strict Bonferroni’s correction to our data in order to avoid the risk of false-positive associations. Moreover, there are also some limitations with our findings in regard to the role of MC4R rs489693 as pharmacogenetic marker, which could be also a prognostic factor. Indeed, it is possible that the MC4R rs489693 AA genotype may be associated with a worse disease outcome, independently from the efficacy of the administration of RT and TMZ. However, the importance of pharmacogenetic pilot studies is that they may open new areas of research, such as, in this case, the possible role of MC4R in the GBM resistance to standard therapy. Furthermore, they could guide the planning of future, randomized, controlled, and multiinstitutional pharmacogenetic studies.

In conclusion, our pilot study suggests that the MC4R rs489693 AA genotype is significantly associated with a shorter PFS and OS in patients treated with a combined RT and TMZ schedule. These findings represent a relevant effort to identify novel clinical markers for RT–CT therapy in GBM, which can be applied in future phase III clinical trials.

Acknowledgements The authors thank Prof. Davide Caramella and Dr. Maria Grazia Fabrini as well as nurses, patients, and their families for the participation to the study. The present study has been funded, in part, by the “Fondi di Ateneo” of the University of Pisa and Fondazione Arpa through the “Progetto Luca Gambicorti”.

References

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/s1470-2045(09)70025-7
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
3. Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-Oncology 15(1):4–27. doi:10.1093/neuonc/nos273
4. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG et al (2015) Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology 17(8):1051–1063. doi:10.1093/neuonc/nov031
5. Cai M, Hruby VJ (2016) The melanocortin receptor system: a target for multiple degenerative diseases. Curr Protein Pept Sci 17(5): 488–496
6. Giuliani D, Minutoli L, Ottani A, Spaccapelo L, Bitto A, Galantucci M, Altavilla D, Squadrinio F et al (2012) Melanocortins as potential therapeutic agents in severe hypoxic conditions. Front Neuroendocrinol 33(2):179–193. doi:10.1016/j.yfrne.2012.04.001
7. Caruso C, Carniglia L, Durand D, Scimonelli TN, Lasaga M (2013) Astrocytes: new targets of melanocortin 4 receptor actions. J Mol Endocrinol 51(2):R33–R50. doi:10.1530/jme-13-0064
8. Tao YX (2010) The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 31(4):506–543. doi:10.1210/er.2009-0037
9. Anderson EJ, Cakir I, Carrington S, Cone R, Ghamari-Langroudi M, Gillyard T, Gimenez LE, Litt M (2016) Regulation of feeding and energy homeostasis by alpha-MSH. J Mol Endocrinol. doi:10.1530/jme-16-0014
10. Lasaga M, Debeljuk L, Durand D, Scimonelli TN, Caruso C (2008) Role of alpha-melanocyte stimulating hormone and melanocortin 4 receptor in brain inflammation. Peptides 29(10):1825–1835. doi:10.1016/j.peptides.2008.06.009
11. Giuliani D, Zaffe D, Ottani A, Spaccapelo L, Galantucci M, Minutoli L, Bitto A, Irrera N et al (2011) Treatment of cerebral ischemia with melancortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery. Acta Neuropathol 122(4):443–453. doi:10.1007/s00401-011-0873-4

12. Giuliani D, Neri L, Canfini F, Calveiro A, Ottani A, Vandini E, Sena P, Zaffe D et al (2015) NDP-alpha-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melancortin MC4 receptors. Mol Cell Neurosci 67:13–21. doi:10.1016/j.mcn.2015.05.004

13. Spaccapelo L, Galantucci M, Neri L, Contri M, Pizzala R, D’Amico R, Ottani A, Sandrini M et al (2013) Up-regulation of the canonical Wnt-3A and Sonic hedgehog signaling underlies melancortin-induced neurogenesis after cerebral ischemia. Eur J Pharmacol 707(1–3):78–86. doi:10.1016/j.ejphar.2013.03.030

14. MacNeil RR, Muller DJ (2016) Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry 2(2):61–78. doi:10.1159/000445802

15. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Koeppen B, Tang W et al (2008) Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 40(6):768–775. doi:10.1038/ng.140

16. Beckers S, Zegers D, de Freitas F, Mertens IL, Van Gaal LF, Van Hul W (2011) Association study of MC4R with complex obesity and replication of the rs17782313 association signal. Mol Gen Metab 103(1):71–75. doi:10.1016/j.mgm.2011.01.007

17. Been LF, Nath SK, Ralhan SK, Wander GS, Mehra NK, Singh J, Mulvihill JJ, Sanghera DK (2010) Replication of association between a common variant near melanocortin-4 receptor gene and obesity-related traits in Asian Sikhs. Obesity (Silver Spring) 18(2):425–429. doi:10.1038/oby.2009.254

18. da Cunha PA, de Carlos Back LK, Sereia AF, Kubelka C, Ribeiro MC, Fernandes BL, de Souza IR (2013) Interaction between obesity-related genes, FTO and MC4R, associated to an increase of breast cancer risk. Mol Biol Rep 40(12):6657–6664. doi:10.1007/s11033-013-2780-3

19. Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM et al (2011) The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One 6(2):1280. doi:10.1371/journal.pone.0016756

20. Wang G, Wang JJ, Fu XL, Guang R, To ST (2016) Advances in the treatment of glioblastoma multiforme (review). Oncol Rep 36(3):789–797. doi:10.3892/or.2016.5309

21. Huang WJ, Chen WW, Zhang X (2016) Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches. Oncotarget 7(44):72238–72250. doi:10.18632/oncotarget.9126

22. Schurman DJ, Horsman D, Czerniak B, Suh G, Amin MB, Bigner HD, Connolly ES Jr, Kondziolka D et al (2013) Sorafenib plus bevacizumab as initial therapy for recurrent glioblastoma. J Neuro-Oncol 114(5):485–496. doi:10.1007/s10974-013-0325-x

23. Schurman DJ, Horsman D, Czerniak B, Suh G, Amin MB, Bigner HD, Connolly ES Jr, Kondziolka D et al (2013) Sorafenib plus bevacizumab as initial therapy for recurrent glioblastoma. J Neuro-Oncol 114(5):485–496. doi:10.1007/s10974-013-0325-x

24. Kass RE, Raittary AE (1995) Bayes factors. J Am Stat Assoc 90(430):773–795

25. Stephans M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76(3):449–462. doi:10.1086/428594

26. Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hittinches MP et al (2015) The MGMT promoter SNP rs10902522 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology 17(12):1589–1598. doi:10.1093/neuonc/nov064

27. Berghoff AS, Hainfellner JA, Marosi C, Preussner M (2015) Assessing MGMT methylation status and its current impact on treatment in glioblastoma. CNS Oncol 4(1):47–52. doi:10.2217/cns.14.50

28. Wang J, Su HK, Zhao HF, Chen ZP, To SS (2015) Progress in the application of molecular biomarkers in gliomas. Biochem Biophys Res Commun 465(1):1–4. doi:10.1016/j.bbrc.2015.07.148

29. Schurman DJ, Horsman D, Czerniak B, Suh G, Amin MB, Bigner HD, Connolly ES Jr, Kondziolka D et al (2013) Sorafenib plus bevacizumab as initial therapy for recurrent glioblastoma. J Neuro-Oncol 114(5):485–496. doi:10.1007/s10974-013-0325-x

30. Schurman DJ, Horsman D, Czerniak B, Suh G, Amin MB, Bigner HD, Connolly ES Jr, Kondziolka D et al (2013) Sorafenib plus bevacizumab as initial therapy for recurrent glioblastoma. J Neuro-Oncol 114(5):485–496. doi:10.1007/s10974-013-0325-x
44. Siljee-Wong JE (2011) Melanocortin MC(4) receptor expression sites and local function. Eur J Pharmacol 660(1):234–240. doi:10.1016/j.ejphar.2010.10.104

45. Caruso C, Durand D, Schioth HB, Rey R, Seilicovich A, Lasaga M (2007) Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma in astrocytes. Endocrinology 148(10):4918–4926. doi:10.1210/en.2007-0566

46. Giuliani D, Ottani A, Zaffe D, Galantucci M, Strinati F, Lodi R, Guarini S (2013) Hydrogen sulfide slows down progression of experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms. Neurobiol Learn Mem 104:82–91. doi:10.1016/j.nlm.2013.05.006

47. Giuliani D, Ottani A, Mioni C, Bazzani C, Galantucci M, Minutoli L, Bitto A, Zaffe D et al (2007) Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. Eur J Pharmacol 570(1–3):57–65. doi:10.1016/j.ejphar.2007.05.025

48. Bitto A, Polito F, Irrera N, Calo M, Spaccapelo L, Marini HR, Giuliani D, Ottani A et al (2012) Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*. Crit Care Med 40(3):945–951. doi:10.1097/CCM.0b013e318236efde

49. Bocci G, Loupakis F (2011) Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics 12(8):1077–1080. doi:10.2217/nnn.11.75